Severity, Criticality, and Fatality of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Beta Variant

Beta (B.1.351)–variant coronavirus disease 2019 (COVID-19) disease was investigated in Qatar. Compared with the Alpha (B.1.1.7) variant, odds (95% confidence interval) of progressing to severe disease, critical disease, and COVID-19–related death were 1.24-fold (1.11–1.39), 1.49-fold (1.13–1.97), an...

Descripción completa

Detalles Bibliográficos
Autores principales: Abu-Raddad, Laith J, Chemaitelly, Hiam, Ayoub, Houssein H, Yassine, Hadi M, Benslimane, Fatiha M, Al Khatib, Hebah A, Tang, Patrick, Hasan, Mohammad R, Coyle, Peter, AlMukdad, Sawsan, Al Kanaani, Zaina, Al Kuwari, Einas, Jeremijenko, Andrew, Kaleeckal, Anvar Hassan, Latif, Ali Nizar, Shaik, Riyazuddin Mohammad, Abdul Rahim, Hanan F, Nasrallah, Gheyath K, Al Kuwari, Mohamed Ghaith, Butt, Adeel A, Al Romaihi, Hamad Eid, Al-Thani, Mohamed H, Al Khal, Abdullatif, Bertollini, Roberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9402694/
https://www.ncbi.nlm.nih.gov/pubmed/34657152
http://dx.doi.org/10.1093/cid/ciab909
_version_ 1784773217234190336
author Abu-Raddad, Laith J
Chemaitelly, Hiam
Ayoub, Houssein H
Yassine, Hadi M
Benslimane, Fatiha M
Al Khatib, Hebah A
Tang, Patrick
Hasan, Mohammad R
Coyle, Peter
AlMukdad, Sawsan
Al Kanaani, Zaina
Al Kuwari, Einas
Jeremijenko, Andrew
Kaleeckal, Anvar Hassan
Latif, Ali Nizar
Shaik, Riyazuddin Mohammad
Abdul Rahim, Hanan F
Nasrallah, Gheyath K
Al Kuwari, Mohamed Ghaith
Butt, Adeel A
Al Romaihi, Hamad Eid
Al-Thani, Mohamed H
Al Khal, Abdullatif
Bertollini, Roberto
author_facet Abu-Raddad, Laith J
Chemaitelly, Hiam
Ayoub, Houssein H
Yassine, Hadi M
Benslimane, Fatiha M
Al Khatib, Hebah A
Tang, Patrick
Hasan, Mohammad R
Coyle, Peter
AlMukdad, Sawsan
Al Kanaani, Zaina
Al Kuwari, Einas
Jeremijenko, Andrew
Kaleeckal, Anvar Hassan
Latif, Ali Nizar
Shaik, Riyazuddin Mohammad
Abdul Rahim, Hanan F
Nasrallah, Gheyath K
Al Kuwari, Mohamed Ghaith
Butt, Adeel A
Al Romaihi, Hamad Eid
Al-Thani, Mohamed H
Al Khal, Abdullatif
Bertollini, Roberto
author_sort Abu-Raddad, Laith J
collection PubMed
description Beta (B.1.351)–variant coronavirus disease 2019 (COVID-19) disease was investigated in Qatar. Compared with the Alpha (B.1.1.7) variant, odds (95% confidence interval) of progressing to severe disease, critical disease, and COVID-19–related death were 1.24-fold (1.11–1.39), 1.49-fold (1.13–1.97), and 1.57-fold (1.03–2.43) higher, respectively, for the Beta variant.
format Online
Article
Text
id pubmed-9402694
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-94026942022-08-25 Severity, Criticality, and Fatality of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Beta Variant Abu-Raddad, Laith J Chemaitelly, Hiam Ayoub, Houssein H Yassine, Hadi M Benslimane, Fatiha M Al Khatib, Hebah A Tang, Patrick Hasan, Mohammad R Coyle, Peter AlMukdad, Sawsan Al Kanaani, Zaina Al Kuwari, Einas Jeremijenko, Andrew Kaleeckal, Anvar Hassan Latif, Ali Nizar Shaik, Riyazuddin Mohammad Abdul Rahim, Hanan F Nasrallah, Gheyath K Al Kuwari, Mohamed Ghaith Butt, Adeel A Al Romaihi, Hamad Eid Al-Thani, Mohamed H Al Khal, Abdullatif Bertollini, Roberto Clin Infect Dis Brief Report Beta (B.1.351)–variant coronavirus disease 2019 (COVID-19) disease was investigated in Qatar. Compared with the Alpha (B.1.1.7) variant, odds (95% confidence interval) of progressing to severe disease, critical disease, and COVID-19–related death were 1.24-fold (1.11–1.39), 1.49-fold (1.13–1.97), and 1.57-fold (1.03–2.43) higher, respectively, for the Beta variant. Oxford University Press 2021-10-17 /pmc/articles/PMC9402694/ /pubmed/34657152 http://dx.doi.org/10.1093/cid/ciab909 Text en © The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Brief Report
Abu-Raddad, Laith J
Chemaitelly, Hiam
Ayoub, Houssein H
Yassine, Hadi M
Benslimane, Fatiha M
Al Khatib, Hebah A
Tang, Patrick
Hasan, Mohammad R
Coyle, Peter
AlMukdad, Sawsan
Al Kanaani, Zaina
Al Kuwari, Einas
Jeremijenko, Andrew
Kaleeckal, Anvar Hassan
Latif, Ali Nizar
Shaik, Riyazuddin Mohammad
Abdul Rahim, Hanan F
Nasrallah, Gheyath K
Al Kuwari, Mohamed Ghaith
Butt, Adeel A
Al Romaihi, Hamad Eid
Al-Thani, Mohamed H
Al Khal, Abdullatif
Bertollini, Roberto
Severity, Criticality, and Fatality of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Beta Variant
title Severity, Criticality, and Fatality of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Beta Variant
title_full Severity, Criticality, and Fatality of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Beta Variant
title_fullStr Severity, Criticality, and Fatality of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Beta Variant
title_full_unstemmed Severity, Criticality, and Fatality of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Beta Variant
title_short Severity, Criticality, and Fatality of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Beta Variant
title_sort severity, criticality, and fatality of the severe acute respiratory syndrome coronavirus 2 (sars-cov-2) beta variant
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9402694/
https://www.ncbi.nlm.nih.gov/pubmed/34657152
http://dx.doi.org/10.1093/cid/ciab909
work_keys_str_mv AT aburaddadlaithj severitycriticalityandfatalityofthesevereacuterespiratorysyndromecoronavirus2sarscov2betavariant
AT chemaitellyhiam severitycriticalityandfatalityofthesevereacuterespiratorysyndromecoronavirus2sarscov2betavariant
AT ayoubhousseinh severitycriticalityandfatalityofthesevereacuterespiratorysyndromecoronavirus2sarscov2betavariant
AT yassinehadim severitycriticalityandfatalityofthesevereacuterespiratorysyndromecoronavirus2sarscov2betavariant
AT benslimanefatiham severitycriticalityandfatalityofthesevereacuterespiratorysyndromecoronavirus2sarscov2betavariant
AT alkhatibhebaha severitycriticalityandfatalityofthesevereacuterespiratorysyndromecoronavirus2sarscov2betavariant
AT tangpatrick severitycriticalityandfatalityofthesevereacuterespiratorysyndromecoronavirus2sarscov2betavariant
AT hasanmohammadr severitycriticalityandfatalityofthesevereacuterespiratorysyndromecoronavirus2sarscov2betavariant
AT coylepeter severitycriticalityandfatalityofthesevereacuterespiratorysyndromecoronavirus2sarscov2betavariant
AT almukdadsawsan severitycriticalityandfatalityofthesevereacuterespiratorysyndromecoronavirus2sarscov2betavariant
AT alkanaanizaina severitycriticalityandfatalityofthesevereacuterespiratorysyndromecoronavirus2sarscov2betavariant
AT alkuwarieinas severitycriticalityandfatalityofthesevereacuterespiratorysyndromecoronavirus2sarscov2betavariant
AT jeremijenkoandrew severitycriticalityandfatalityofthesevereacuterespiratorysyndromecoronavirus2sarscov2betavariant
AT kaleeckalanvarhassan severitycriticalityandfatalityofthesevereacuterespiratorysyndromecoronavirus2sarscov2betavariant
AT latifalinizar severitycriticalityandfatalityofthesevereacuterespiratorysyndromecoronavirus2sarscov2betavariant
AT shaikriyazuddinmohammad severitycriticalityandfatalityofthesevereacuterespiratorysyndromecoronavirus2sarscov2betavariant
AT abdulrahimhananf severitycriticalityandfatalityofthesevereacuterespiratorysyndromecoronavirus2sarscov2betavariant
AT nasrallahgheyathk severitycriticalityandfatalityofthesevereacuterespiratorysyndromecoronavirus2sarscov2betavariant
AT alkuwarimohamedghaith severitycriticalityandfatalityofthesevereacuterespiratorysyndromecoronavirus2sarscov2betavariant
AT buttadeela severitycriticalityandfatalityofthesevereacuterespiratorysyndromecoronavirus2sarscov2betavariant
AT alromaihihamadeid severitycriticalityandfatalityofthesevereacuterespiratorysyndromecoronavirus2sarscov2betavariant
AT althanimohamedh severitycriticalityandfatalityofthesevereacuterespiratorysyndromecoronavirus2sarscov2betavariant
AT alkhalabdullatif severitycriticalityandfatalityofthesevereacuterespiratorysyndromecoronavirus2sarscov2betavariant
AT bertolliniroberto severitycriticalityandfatalityofthesevereacuterespiratorysyndromecoronavirus2sarscov2betavariant